Publications, Pharmaceutical

Investigating The Propellant Pathways Leading To a Sustainable Future of MDIs

The development of metered dose inhalers (MDIs) with a lighter environmental footprint is increasingly urgent as the pharmaceutical industry proceeds to Net Zero and greater sustainability.

This article looks at what a transition to propellants with lower Global Warming Potential will involve and the lessons that can be learned from the industry’s earlier transition from CFCs to HFAs. Key issues that need to be addressed as formulators learn to work with propellants such as HFA 152a and HFO 1234ze include solubility of the active, the profile of the emitted spray, droplet size and evaporation, and electrostatic characteristics.

Aptar Pharma offers a comprehensive suite of services for those looking to accelerate their transition to low carbon MDIs including the Nanopharm SmartTrack™ platform which provides a wealth of information for formulation optimization.

For more information on ONdrugDelivery.


Download Publication
Author(s): Chris Baron Jag Shur
8 Apr 2022

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Your Interest

17 Oct 2023

Consumer Driven Path to Circularity and Future Pharmaceutical Packaging

Publications, Pharmaceutical, Market Insights, Product Solutions, Sustainability, Device Innovations, Brand Differentiation

Read More
11 May 2023

Why Pharma should care about circular packaging – Futurity leading the way

Publications, Pharmaceutical, Sustainability, Device Innovations, Brand Differentiation, Product Solutions

Read More
13 Mar 2023

Moving Towards Greater Recyclability in Drug Delivery – Sustainable Solutions b...

Webinars, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions, Sustainability

Read More
16 Nov 2022

From pMDI Device to Therapeutic Effect

Webinars, Pharmaceutical, Sustainability, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 5
Back To Top